page19
Dose changes
Changes in dose statements introduced into BNF No.
61:
Aciclovir [herpes simplex treatment
and suppression],
p.
393
AmBisome
c
,
p.
378
Atazanavir [paediatric dose],
p.
386
Benzylpenicillin, p.
333
Bisacodyl, p.
69
Cefadroxil,
p.
341
Cervarix
c
,
p.
757
Cetirizine [dose in renal impairment],
p.
192
Cetirizine [paediatric dose],
p.
192
Co-amoxiclav [intravenous dose],
p.
337
Cyproterone acetate [prevention of
flare with initial
gonadorelin analogue therapy], p.
573
Daptomycin [dose in renal impairment],
p.
357
Ethosuximide [paediatric dose],
p.
283
Famciclovir,
p.
394
Fersamal
c
,
p.
578
Fluoxetine [obsessive compulsive disorder], p.
241
Foradil
c
[dose for children under 12 years],
p.
177
Fulvestrant,
p.
570
Galantamine [dose in hepatic impairment],
p.
318
Hyoscine butylbromide [by continuous infusion device
for bowel
colic and excessive respiratory secretions],
p.
23
Hyoscine hydrobromide [by subcutaneous injection for
excessive respiratory secretions],
p.
21
Infliximab [severe active Crohn’s disease],
p.
66
Ipratropium [dose frequency for severe acute asthma in
adults],
p.
171 and p.
173
Itraconazole [histoplasmosis], p.
375
Melatonin,
p.
212
Meropenem,
p.
346
Methoxy polyethylene glycol-epoetin beta,
p.
586
Metronidazole,
p.
367
Pabrinex
c
[Wernicke’s encephalopathy],
p.
616
Pancuronium,
p.
789
Pantoprazole,
p.
57
Phenytoin sodium,
p.
297
Prednisolone
[maximum dose
in
paediatric
acute
asthma],
p.
171 and p.
173
Primidone [essential tremor],
p.
288
Remifentanil
[analgesia
and
sedation
in ventilated,
intensive-care patients], p.
787
Salofalk
c
tablets,
p.
62
Saquinavir,
p.
389
Selenium sulphide [pityriasis versicolor text],
p.
736
Sodium valproate [epilepsy],
p.
291
Suxamethonium [by intravenous injection],
p.
790
Temazepam [premedication],
p.
785
Thiamine [mild deficiency], p.
616
Vagifem
c
,
p.
491
Valaciclovir,
p.
394
Xylometazoline [nasal spray], p.
692
Classification changes
Classification changes have been made in the following
sections for BNF No.
61:
Section 2.1.2 Phosphodiesterase type-3 inhibitors [title
change]
Section 3.3.3 Phosphodiesterase type-4 inhibitors [new
sub-section]
Section 4.7.1 Non-opioid analgesics
and compound
analgesic preparations [title change]
Section 4.10.1 Alcohol dependence [new section]
Section 4.10.2 Nicotine dependence [new section]
Section 4.10.3 Opioid dependence [new section]
Section 4.10.3 Opioid substitution therapy [new sub-
section]
Section 4.10.3 Adjunctive therapy and symptomatic
treatment [new sub-section]
Section 4.10.3 Opioid-receptor antagonists [new sub-
section]
Section 10.3 Drugs for the relief of
soft-tissue inflam-
mation and topical pain relief [title change]
Section 10.3.2 Rubefacients, topical NSAIDs, capsaicin,
and poultices [title change]
Section 15.1.4.1 Anxiolytics [title change]
New names
Name changes introduced into BNF No.
61:
Hydrocortisone mucoadhesive buccal
tablets [formerly
Corlan
c
],
p.
694
Laxido
c
Orange
[formerly
Laxido
c
],
p.
71
Oilatum
c
Junior
bath additive
[formerly
Oilatum
c
Junior emollient bath additive
],
p.
704
Deleted preparations
Preparations listed below have been discontinued dur-
ing the compilation of BNF No. 61, or are still available
but
are not
considered suiatable for inclusion by the
Joint Formulary Committee (see footnote).
Actinac
c
Andropatch
c
Avandamet
c
Avandia
c
Baxan
c
Clonidine injection
1
Dexedrine
c
Digitoxin
1
Dimercaprol
1
Flixotide
c
Diskhaler
Imuderm
c
1.
Not
considered
suitable
for
inclusion
by
the
Joint
Formulary Committee
BNF 61
xvii